ADOCIA |
Market Closed -
Other stock markets
|
After market 12:01:25 pm | |||
| 7.37 EUR | -3.28% |
|
7.37 | 0.00% |
| Jun. 04 | Adocia appoints Director of Operations | CF |
| Jun. 03 | Adocia Announces Appointment of Mathieu-William Gilbert as Chief Operating Officer | CI |
| Sales 2024 * | 50M 53.48M | Sales 2025 * | 86M 91.98M | Capitalization | 112M 120M |
|---|---|---|---|---|---|
| Net income 2024 * | 26M 27.81M | Net income 2025 * | 40M 42.78M | EV / Sales 2024 * | 1.79 x |
| Net cash position 2024 * | 22.5M 24.06M | Net cash position 2025 * | 62.3M 66.63M | EV / Sales 2025 * | 0.58 x |
| P/E ratio 2024 * |
2.05
x | P/E ratio 2025 * |
1.36
x | Employees | 78 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.06% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -3.28% | ||
| 1 week | -13.90% | ||
| Current month | -18.11% | ||
| 1 month | -19.89% | ||
| 3 months | -17.65% | ||
| 6 months | -9.46% | ||
| Current year | -36.14% |
1 week
6.99
8.56
1 month
6.999.99
Current year
6.9912.40
1 year
3.5916.16
3 years
2.7516.16
5 years
2.7522.60
10 years
2.7594.24
| Managers | Title | Age | Since |
|---|---|---|---|
Olivier Soula
FOU | Founder | 53 | 05-12-15 |
Gérard Soula
FOU | Founder | 78 | 05-12-15 |
| Director of Finance/CFO | - | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gérard Soula
FOU | Founder | 78 | 05-12-15 |
| Director/Board Member | 67 | 21-05-20 | |
| Director/Board Member | 58 | 13-06-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 7.37 | -3.28% | 146 092 |
| 24-06-13 | 7.62 | -8.74% | 102,437 |
| 24-06-12 | 8.35 | +4.24% | 152,947 |
| 24-06-11 | 8.01 | -2.91% | 102,642 |
| 24-06-10 | 8.25 | -3.62% | 60,880 |
Real-time Euronext Paris, June 14, 2024 at 11:35 am EDT
More quotes
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes.
At the end of 2023, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).
Calendar
2024-07-23
- Q2 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
7.62
EUR
Average target price
9.7
EUR
Spread / Average Target
+27.30%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -36.14% | 121M | |
| +18.28% | 124B | |
| +17.86% | 111B | |
| -11.49% | 23.17B | |
| +5.07% | 22.94B | |
| -39.94% | 17.42B | |
| -10.21% | 17.42B | |
| -14.97% | 16.9B | |
| +2.49% | 13.71B | |
| +27.82% | 11.82B |
- Stock Market
- Equities
- ADOC Stock
